transfusion-transmissible HCV and HIV in Italy Haemovigilance and the residual risk of
|
|
- Branden Marsh
- 5 years ago
- Views:
Transcription
1 Haemovigilance and the residual risk of transfusion-transmissible Giuliano Grazzini, MD National Blood Centre, National Institute of Health, Rome, Italy & International Federation of Blood Donor Organizations (FIODS/IFBDO) CONFLICTS OF INTEREST STATEMENT The speaker declares that he has NO affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this presentation.
2 BACKGROUND - 1 The risk of transmitting hepatitis C virus (HCV), human immunodeficiency virus (HIV) and hepatitis B virus (HBV) through blood transfusion has significantly decreased since the introduction of nucleic acid testing (NAT) along with the previously implemented antigen/antibody-based assays for blood screening and the adoption of restrictive criteria for donor selection. BACKGROUND - 2 Following serological and especially molecular screening of blood donors, in most countries the risk of transfusion-transmitted HCV, HIV and HBV infections has become too low (i.e. residual) for direct assessment through conventional approaches such as prospective follow-up and retrospective look-back studies of blood recipients.
3 BACKGROUND - 3 RESIDUAL RISK (RR) of transfusion-transmitted infections (TTIs) - Quantitative evaluation of the possibility that a blood component for transfusion, though negative at screening tests, is capable of transmitting an infection to the recipient. - Monitoring the residual risk of TTIs in donor populations through the systematic collection and elaboration of epidemiological data is a crucial element to assess the efficacy of the preventive measures adopted by national blood systems/authorities to ensure the safety of their blood supplies. BACKGROUND - 4 The RR of collecting an infectious donation that is undetectable by screening tests has since long been calculated by mathematical models based on the incidence rate of HCV, HIV and HBV infections among donors and on the length of the diagnostic window period (WP) of each viral infection (temporal gap spanning from the time point of donor infection to the first detectability of specific viral markers): incidence / window period model
4 WP WP WP The diagnostic window period (WP) consists of 2 phases: 1) the eclipse phase: the virus has already infected the donor but is not yet detectable in blood even by highly sensitive tests; 2) the ramp-up phase: the viral load in blood (viremia) increases exponentially - with specific doubling time - up to a peak/plateau Kleinman SH, Lelie N, Busch MP. Transfusion. 2009;49(11): Modified.
5 32 blood units tested NAT-only positive: 19 for HCVRNA (8 FT 11 RP donors), 13 for HIV-RNA (3 FT 10 RP donors). 2,641 blood donors tested positive for HCV/HIV markers: - 1,949 FT donors out of 1,934,612 FT donors x 105 or 1 in 1, RP donors out of the 10,323,975 RP donors x 105 or 0.07 in 1,000. * Busch MP, Glynn SA, Stramer SL, et al. Transfusion 2005; 45: Prevalence was calculated in the population of FT donors as the rate between the number of positive subjects and the total number of FT donors in the same period of time (x 100,000 donors)*.
6 Incidence is expressed as the number of new infected cases 100,000 person-years at risk. It was calculated in the population of RP donors as the number of positive subjects with a previous negative donation or negative testing, within the preceding 24 months, divided by the total number of donations from RP donors in the study period multiplied by the mean interdonation interval expressed in years (= person-years at risk)*. * Glynn SA, Kleinman SH, Wright DJ, Busch MP. Transfusion 2002; 42: * Busch MP, Glynn SA, Stramer SL, et al. Transfusion 2005; 45: PREVALENCE of HCV and HIV infection in first-time donors Italy, n/ HCV HIV
7 n/10 5 INCIDENCE of HCV and HIV infection in repeat donors Italy, HCV HIV copy/20 mls T-I HIV 1 copy/20 mls Figure 1. Periods T in Days (Standard Error) for HIV and HCV* T-I ID-NAT MP-NAT p24 Ag WB S/LSEIA T-II T-IIIa T-IIIb T-IV 5.6 (0.40) 3.4(0.22) 5.3 (1.02) 9.0 (0.60) 6.0 (1.08) (10.0) ID-NAT MP-NAT EIA 3.0 To calculate RR the "window period ratio method was considered the reference method since we had used it in the past, making comparisons with previous data easier. The RR was estimated, both in first-time and repeat donors, multiplying the NAT yield rate (i.e. no. of NAT-only positive cases/number donations screened) by the ratio between the infectious pre- NAT window period and that estimated as the time elapsing from NAT detectability and serological detectability. HCV T-I T-II 4.9 (0.45) 2.5 (0.22) 7.4 (0.67) T-III 50.9 (2.47) * Calculations based on the HIV and HCV Gen-Probe TMA 50% sensitivities. Busch MP, Glynn SA, Stramer SL, et al. Transfusion 2005; 45: The weighted average pre-nat infectious window period for the entire study period (different NAT screening methods had been employed during the 7-year study period) was estimated to be 4.74 days for HCV and 7.0 days for HIV. The ratios concerning the two window periods of interest resulted 4.74/53.6 days for HCV and 7.0/8.0 days for HIV, respectively.
8 Residual risk of transfusing an infected blood unit collected during the Window Period of the HCV infection in Italy, Window period ratio model* *Busch MP, Glynn SA, Stramer SL, et al. Transfusion 2005; 45: RP positive donations/donations tested 11/19,873,740 RP RR x 10 6 (95% CI) ( ) or 1 in 20,430,235 FT positive donations/donations tested 8/1,934,612 FT RR x 10 6 (95% CI) ( ) or 1 in 2,734,578 Total RR x 10 6 (95% CI) ( ) or 1 in 12,979,949 Residual risk of transfusing an infected blood unit collected during the Window Period of the HIV infection in Italy, Window period ratio model* RP positive donations/donations tested 10/19,873,740 RP RR x 10 6 (95% CI) ( ) or 1 in 2,271,285 *Busch MP, Glynn SA, Stramer SL, et al. Transfusion 2005; 45: FT positive donations/donations tested 3/1,934,612 FT RR x 10 6 (95% CI) ( ) or 1 in 736,995 Total RR x 10 6 (95% CI) ( ) or 1 in 1,917,250
9 Residual risk (n/10 6 ± 95% C.I. ) for HCV, HIV and HBV in Italy Velati C et Al. Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey. Transfusion 2008 Oct;48(10): Updated in 2009 Haemovigilance and the residual risk of transfusion-transmissible HCV and HIV in Italy Residual risk (n/10 6 ± 95% C.I. ) for HCV, HIV and HBV in Italy HCV HIV 0,3 (0,1-0,6) 1,9 (0,6-3,9) 0,2 (0,1-0,4) 1,8 (0,8-2,8) HBV - - 0,2 (0,1-0,3) 1,4 (0,7-2,1) 1,6 (0,3-1,8) 0,2 (0,1-0,3) 1,3 (0,7-1,9) 0,1 (0,1-0,2) 0,8 (0,6-1,6) Società Italiana di Medicina Trasfusionale e Immunoematologia Settore Ricerca & Sviluppo Gruppo Italiano per lo Studio delle Malattie Trasmissibili con la Trasfusione 1,9 (0,9-2,7) 1,6 (0,6-2,1) 0,1 (0,1-0,2) 0,7 (0,5-1,6) 1.6 (0,6-2,1)
10 Evolution of the Residual risk in Italy vs RR RR HCV 1 in 10,000,000 1 in 13,000,000 HIV 1 in 1,200,000 1 in 1,900,000 - The overall frequency of HCV and HIV markers is 15-fold higher in FT than in RP donors - The frequency of NAT-only positive blood units is 7.4-fold (HCV) and 3-fold (HIV) higher in FT donors - RR for HCV and HIV results remarkably higher in FT vs. RP donors FT Donors RP Donors RR HCV 1 in 2,734,578 1 in 20,430,235 RR HIV 1 in 736,995 1 in 2,271,285
11 HCV+ (n=1,658) HIV+ (n=291) HCV (n=238) HIV+ (n=454) Haemovigilance and the residual risk of transfusion-transmissible Risk factors of FT and RP donors positive for HCV and HIV markers in Italy, FT donors RP donors Gender: Male Female Risk factor: N (%) 1,106 (66.7) 552 (33.3) N (%) 232 (79.7) 59 (20.3) N (%) 150 (63) 88 (37) N (%) 406 (89.4) 48 (10.6) Sexual of whom: Heterosexual MSM 171 (9.2) 132 (77.2) 39 (22.8) 163 (49.2) 104 (63.8) 59 (36.2) 41 (14.3) 38 (92.7) 3 (7.3) 311 (60.6) 193 (62.1) 118 (37.9) Parenteral 425 (22.7) 36 (10.9) 89 (31.1) 50 (9.7) Household contact 19 (1.0) 1 (0.3) 4 (1.4) 4 (0.8) Not identified? 1,254 (67.1) 131 (39.6) 152 (53.2) 148 (28.9) The RR for HCV and HIV was also calculated according to EMA (2016) and WHO (2017) Guidelines, obtaining data significantly different - MUCH LOWER RISK - from those obtained with the Busch et Al. s method, which have been assumed as the worst scenario and therefore as national reference data.
12 Thanks for your attention! Giuliano Grazzini, MD National Blood Centre, National Institute of Health, Rome, Italy & International Federation of Blood Donor Organizations (FIODS/IFBDO)
The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations Jackson B R, Busch M P, Stramer S L, AuBuchon J P
The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations Jackson B R, Busch M P, Stramer S L, AuBuchon J P Record Status This is a critical abstract of an economic evaluation that meets
More informationLookback studies to assess viral risks The French experience
Lookback studies to assess viral risks The French experience 2000-2012 S Laperche 1, MF Leconte des Floris 2, J Pillonel 3, L Hauser 2, C Lefort 2, JY Py 2, I Hervé 2, R Djoudi 2 For the French haemovigilance
More informationrisk of Transfusion-Transmitted Transmitted Viral Infections (HIV, HCV and HBV)
Prevention and ResidualR risk of Transfusion-Transmitted Transmitted Viral Infections (HIV, HCV and HBV) Syria Laperche L (Centre National de référence r rence pour les hépatites h B et C en Transfusion)
More informationDiagnosis of Acute HCV Infection
Hepatitis C Online PDF created December 20, 2017, 7:54 pm Diagnosis of Acute HCV Infection This is a PDF version of the following document: Module 1: Screening and Diagnosis of Hepatitis C Infection Lesson
More informationR Offergeld, D Faensen, S Ritter, O Hamouda Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany
Eurosurveillance, Volume 10, Issue 2, 01 February 2005 Surveillance report HUMAN IMMUNODEFICIENCY VIRUS, HEPATITIS C AND HEPATITIS B INFECTIONS AMONG BLOOD DONORS IN GERMANY 2000-2002: RISK OF VIRUS TRANSMISSION
More informationGuidance for Industry
Guidance for Industry Use of Nucleic Acid Tests on Pooled and Individual Samples from Donors of Whole Blood and Blood Components (including Source Plasma and Source Leukocytes) to Adequately and Appropriately
More informationWHO GUIDELINES ON ESTIMATION OF RESIDUAL RISK OF HIV, HBV OR HCV INFECTIONS VIA CELLULAR BLOOD COMPONENTS AND PLASMA
ENGLISH ONLY EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 17 to 21 October 2016 WHO GUIDELINES ON ESTIMATION OF RESIDUAL RISK OF HIV, HBV OR HCV INFECTIONS VIA CELLULAR BLOOD COMPONENTS AND PLASMA
More informationRoutine Use of Mini-Pool Nucleic Acid Testing (MP-NAT) Multiplex Assay for Sero-Negative Blood Donors
Journal of the Egyptian Society of Haematology & Research, Vol. 7, No. 2, September: 1-5, 2011 Routine Use of Mini-Pool Nucleic Acid Testing (MP-NAT) Multiplex Assay for Sero-Negative Blood Donors HISHAM
More informationSource Plasma Safety
Source Plasma Safety Plasma May 15-19, 2017 George Schreiber, ScD, PPTA Director, Epidemiology Three components: Plasma Product Safety Donor Quality Manufacturing Pool Quality Fractionation Process Safe
More informationImpact of Testing Strategies to Reduce Transmission Risk for HBV. Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013
Impact of Testing Strategies to Reduce Transmission Risk for HBV Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013 Overview of SANBS SANBS is a private not for profit company
More informationImpact of multi-dye multiplex technology on testing algorithm
Impact of multi-dye multiplex technology on testing algorithm Lydia Blanco. Mª Isabel Gonzalez-Fraile Centro de Hemoterapia y Hemodonación de Castilla y León, España TTI EPIDEMIOLOGICAL DATA IN SPAIN NAT
More informationScreening the Blood Supply for West Nile Virus RNA by Nucleic Acid Amplification Testing
The new england journal of medicine original article Screening the Blood Supply for West Nile Virus RNA by Nucleic Acid Amplification Testing Michael P. Busch, M.D., Ph.D., Sally Caglioti, M.T.(A.S.C.P.),
More informationARCHITECT HIV Ag/Ab Combo: Moving HIV Diagnostics Forward in the U.S.
ARCHITECT HIV Ag/Ab Combo: Moving HIV Diagnostics Forward in the U.S. Catherine Brennan, Ph.D. Research Fellow Infectious Diseases Research Abbott Diagnostics 1 Agenda ARCHITECT HIV Ag/Ab Combo Assay What
More informationQuantification of HBV, HCV genotype and HIV subtype panels
Quantification of HBV, HCV genotype and HIV subtype panels Harry van Drimmelen 1,2, Wim Quint 2, Nico Lelie 3 and the international NAT study group 1. Biologicals Quality Control, 2. DDL Diagnostic Laboratory,
More informationMulticenter efficacy study of HBV, HCV and HIV blood screening scenarios
Multicenter efficacy study of HBV, HCV and HIV blood screening scenarios Steven Kleinman, Nico Lelie, Roberta Bruhn, Brian Custer, Michael Busch and the international ID-NAT user group Blood Systems Research
More informationGuidance for Industry
Guidance for Industry Advisement for the Use of Gen-Probe Procleix Ultrio Plus Assay for NAT Testing on Cadaveric Donors Release Date: 08/03/14 American Medical Education and Research Association 4757
More informationTransfusion Risk for Hepatitis B, Hepatitis C and HIV in the State of Santa Catarina, Brazil,
236 BJID 2004; 8 (June) Transfusion Risk for Hepatitis B, Hepatitis C and HIV in the State of Santa Catarina, Brazil, 1991-2001 Emil Kupek Department of Public Health, Federal University of Santa Catarina,
More informationISBT WP-TTID Annual Report for Subgroup on Virology Drs. Michael Busch, Kurt Roth and Susan Stramer
ISBT WP-TTID Annual Report for Subgroup on Virology Drs. Michael Busch, Kurt Roth and Susan Stramer Questionnaire on NAT Screening of Blood Donations for an International Forum on 10 years of NAT Screening
More informationImpact of changing donor demographics on HIV transmission risk: A ten year analysis of individual donation NAT screening
Impact of changing donor demographics on HIV transmission risk: A ten year analysis of individual donation NAT screening IPFA Lisbon 216 Marion Vermeulen Disclaimer Race classifications are described as
More informationFelix Yao DOCTOR OF PHILOSOPHY
Investigation on the Risk of Viral Infection in Musculoskeletal Grafts Felix Yao The collection of these publications is presented for the degree of DOCTOR OF PHILOSOPHY of The University of Western Australia
More informationOriginal article J Bas Res Med Sci 2017; 4(2):4-8.
Prevalence of HIV, hepatitis B and C infections among volunteer blood donors at the blood transfusion center of Ilam city, Iran Hasan Boustani 1, Enayat Anvari 2, Sedighe Saiadi Sartang 2, Mehdi Omidi
More information2014/LSIF/PD/025 Malaysia s Approach to Testing Strategies
2014/LSIF/PD/025 Malaysia s Approach to Testing Strategies Submitted by: Malaysia Policy Dialogue and Workshop on Attaining a Safe and Sustainable Blood Supply Chain Manila, Philippines 30 September 1
More informationSource of effectiveness data Effectiveness data were derived from a single study combined with a review of previously completed studies.
Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection Busch M P, Korelitz J J, Kleinman S H, Lee S R, Aubuchon J P, Schreiber
More informationBLOOD SAFETY STATUS IN INDONESIA. Yuyun Soedarmono Chairman of the Indonesian Association of Transfusion Medicine
BLOOD SAFETY STATUS IN INDONESIA Yuyun Soedarmono Chairman of the Indonesian Association of Transfusion Medicine OUTLINE Background Blood services in Indonesia Regulation related to blood safety in Indonesia
More informationStructure and duties of Blood service
NATIONAL CENTER FOR TRANSFUSION MEDICINE Prevalence of infectious diseases among Mongolian blood donors Namjil Erdenebayar General director of The National Center for Transfusion Medicine, Mongolia NCTM,
More informationJune 8, Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852
June 8, 2018 Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Submitted via http://www.regulations.gov Re: Docket No. FDA 2016 D 0545,
More informationpatients with blood borne viruses Controlled Document Number: Version Number: 4 Controlled Document Sponsor: Controlled Document Lead:
CONTROLLED DOCUMENT Procedure for the management of patients with blood borne viruses CATEGORY: CLASSIFICATION: PURPOSE Controlled Document Number: Version Number: 4 Controlled Document Sponsor: Controlled
More informationHIV Update in Laboratory Testing. Patricia Slev, PhD, D(ABCC)
HIV Update in Laboratory Testing Patricia Slev, PhD, D(ABCC) Objectives Explain the advances in HIV diagnostics, including fourth generation Ag/Ab combination HIV screening assays Describe the new CDC
More informationChange in deferrals for men who have sex with men: Assessing the risk of HIV transmission by transfusion
Change in deferrals for men who have sex with men: Assessing the risk of HIV transmission by transfusion Josiane Pillonel, Rachid Djoudi, Florence Lot, Chistophe Martinaud, Claire Sauvage, Marie Jauffret-Roustide,
More informationResearch Article Decreasing Prevalence of Transfusion Transmitted Infection in Indian Scenario
e Scientific World Journal, Article ID 173939, 4 pages http://dx.doi.org/10.1155/2014/173939 Research Article Decreasing Prevalence of Transfusion Transmitted Infection in Indian Scenario Tulika Chandra,
More information[Submitted Electronically]
[Submitted Electronically] Dr. Matthew J. Kuehnert, Director Office of Blood, Organ, and Other Tissue Safety Division of Healthcare Quality Promotion National Center for Emerging and Zoonotic Infectious
More informationAssays to Address Emerging Threats to Blood Safety
Assays to Address Emerging Threats to Blood Safety Jeffrey M. Linnen, Ph.D. Director, Product Development Gen-Probe Incorporated San Diego, CA The IPFA/PEI 17th Workshop on Surveillance and Screening of
More informationDaniel P. Kolk,* Janel Dockter, Jeff Linnen, Marcy Ho-Sing-Loy, Kristin Gillotte-Taylor, Sherrol H. McDonough, Larry Mimms, and Cristina Giachetti
JOURNAL OF CLINICAL MICROBIOLOGY, May 2002, p. 1761 1766 Vol. 40, No. 5 0095-1137/02/$04.00 0 DOI: 10.1128/JCM.40.5.1761 1766.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.
More informationWHO GUIDELINE ON ESTIMATION OF RESIDUAL RISK OF HIV, HBV OR HCV INFECTIONS VIA CELLULAR BLOOD COMPONENTS AND PLASMA
WHO/BS/0. ENGLISH ONLY 0 0 0 WHO GUIDELINE ON ESTIMATION OF RESIDUAL RISK OF HIV, HBV OR HCV INFECTIONS VIA CELLULAR BLOOD COMPONENTS AND PLASMA NOTE: This document has been prepared for the purpose of
More informationPolicy Document. Blood Donation Deferral. Background
Policy Document Blood Donation Deferral Background The Australian Medical Students Association (AMSA) is the peak representative body for medical students in Australia. Accordingly, AMSA advocates on issues
More informationPreventing disease transmission by deceased tissue donors by testing blood for viral nucleic acid
Cell and Tissue Banking (2005) 6:255 262 Ó Springer 2005 DOI 10.1007/s10561-005-2834-4 -1 Preventing disease transmission by deceased tissue donors by testing blood for viral nucleic acid D. Michael Strong
More informationAnitha M.*, Sreedhar Babu K. V., Praveen M. D., Sriranjitha T. V. N.
International Journal of Research in Medical Sciences Anitha M et al. Int J Res Med Sci. 2017 Aug;5(8):3438-3442 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Original Research Article DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20173536
More informationPublic Health, Infections and Transplantation
Public Health, Infections and Transplantation Dr Kerry Chant Chief Health Officer & Deputy Director General Population and Public Health NSW Ministry of Health May2014 Public Health Infection and Transplantation
More informationScreening donors and donations for transfusion transmissible infectious agents. Alan Kitchen
Screening donors and donations for transfusion transmissible infectious agents Alan Kitchen Aim Not to teach you microbiology To provide and awareness of the big picture To provide an understanding of
More informationInfectious Disease Considerations in Organ Donation. Nikole A Neidlinger MD FACS Chief Medical Officer
Infectious Disease Considerations in Organ Donation Nikole A Neidlinger MD FACS Chief Medical Officer Screening Donors and Infectious Disease considerations: Deceased Donor Screening Donors at increased
More informationQSEAL Recovered Plasma Specification
QSEAL Recovered Plasma Specification Background The is part of a series of standards that comprise the Plasma Protein Therapeutics Association (PPTA) QSEAL Standards Program. PPTA's Voluntary Standards
More informationHEPATITIS C, ACUTE CRUDE DATA. Number of Cases 5 Annual Incidence a LA County 0.05 California b 0.10 United States b 0.68 Age at Diagnosis Mean 38
2016 Annual Morbidity Report HEPATITIS C, ACUTE a Rates calculated based on less than 19 cases or events are considered unreliable b Calculated from: CDC. Notice to Readers: Final 2016 Reports of Nationally
More informationDetection of HIV-1 and HCV Infections among Antibody-Negative Blood Donors by Nucleic Acid Amplification Testing
The new england journal of medicine original article Detection of HIV-1 and HCV Infections among Antibody-Negative Blood Donors by Nucleic Acid Amplification Testing Susan L. Stramer, Ph.D., Simone A.
More informationErgebnisse der Abfrage zu NAT-only positiven Befunden beim Blutspendescreening (NAT yield) Micha Nübling, PEI
Ergebnisse der Abfrage zu NAT-only positiven Befunden beim Blutspendescreening (NAT yield) Micha Nübling, PEI NAT for cellular blood components in Germany Definition of minimal NAT sensitivity limit (ID)
More informationSensitivity of the Procleix HIV-1/HCV Assay for Detection of Human Immunodeficiency Virus Type 1 and Hepatitis C Virus RNA in a High-Risk Population
JOURNAL OF CLINICAL MICROBIOLOGY, July 2002, p. 2387 2391 Vol. 40, No. 7 0095-1137/02/$04.00 0 DOI: 10.1128/JCM.40.7.2387 2391.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.
More informationANNALS OF HEALTH LAW Advance Directive VOLUME 23 SPRING 2014 PAGES
ANNALS OF HEALTH LAW Advance Directive VOLUME 23 SPRING 2014 PAGES 101-112 United States Blood Donor Policy on Gay Men: Adopting an Italian Individual Risk Assessment Policy Melissa Kong* I. INTRODUCTION
More informationHIV and PEP. LTC Rose Ressner WRNMMC ID staff Oct 2014 UNCLASSIFIED
HIV and PEP LTC Rose Ressner WRNMMC ID staff Oct 2014 UNCLASSIFIED Disclaimer The views expressed in this presentation are those of the speaker and do not reflect the official policy of the Department
More informationMaximizing Cornea and Tissue Donation through Specimen Quality
Maximizing Cornea and Tissue Donation through Specimen Quality Robert W. Bresler, Sydney D. Gastreich, Elias G. Koulouriotis, Linda S. Martin, Susan Diane Brockmeier, Chak-Sum Ho, PhD Abstract Purpose:
More informationFrequency of occult hepatitis B in HBsAg seronegative blood donors in a tertiary care hospital in kerala,south India.
Frequency of occult hepatitis B in HBsAg seronegative blood donors in a tertiary care hospital in kerala,south India. Cinzia Keechilot, Veena Shenoy 1,V Anil kumar 2,Lalita Biswas 3. MBBS student * Transfusion
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091650 Age 49 Years Gender Male 29/8/2017 120000AM 29/8/2017 100248AM 29/8/2017 105306AM Ref By Final HEATITIS, VIRAL, COMREHENSIVE ANEL HEATITIS A ANTIBODY (ANTI
More information23 November Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852
23 November 2016 Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Submitted via http://www.regulations.gov Re: Docket No. FDA-2016-N-1502,
More informationThe Alphabet Soup of Viral Hepatitis Testing
The Alphabet Soup of Viral Hepatitis Testing August 18, 2011 Patricia Slev, PhD, DABCC Medical Director, Serologic Hepatitis and Retrovirus Laboratory, ARUP Laboratories Assistant Professor of Pathology,
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT. APPENDICES a TO GUIDELINE ON EPIDEMIOLOGICAL DATA ON BLOOD TRANSMISSIBLE INFECTIONS
European Medicines Agency Evaluation of Medicines for Human Use London, 20 May 2009 Doc. Ref. EMEA/CPMP/BWP/125/04 Rev.1 Appendices COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT APPENDICES
More informationGuidance for Industry
Guidance for Industry Lookback for Hepatitis C Virus (HCV): Product Quarantine, Consignee Notification, Further Testing, Product Disposition, and Notification of Transfusion Recipients Based on Donor Test
More informationViral Hepatitis Diagnosis and Management
Viral Hepatitis Diagnosis and Management CLINICAL BACKGROUND Viral hepatitis is a relatively common disease (25 per 100,000 individuals in the United States) caused by a diverse group of hepatotropic agents
More informationProbability of false initial and repeat ID-NAT reactive donations. Marion Vermeulen IPFA Rome 2014
Probability of false initial and repeat ID-NAT reactive donations Marion Vermeulen IPFA Rome 2014 Overview of SANBS SANBS is a non profit organization Provides a vein to vein blood transfusion service
More informationCombating Transfusion transmitted infections in thalassemia-current Indian scenario
Combating Transfusion transmitted infections in thalassemia-current Indian scenario Dr.R.Arun Assistant Professor Dept. of Transfusion Medicine Sri Venkateswara Institute of Medical Sciences (SVIMS), Tirupati
More informationDept. of Pathology, Chandulal Chandrakar Memorial Medical College, Durg Chhatishgarh, India 2. Pandit Jawaharlal Nehru Medical College, Raipur, India
Original Article DOI: 10.21276/AABS.1450 Comparison of ELISA & Rapid Screening Tests for the Diagnosis of HIV, HBV & HCV Among Blood Donors in Blood Bank of C.C.M. Medical College Durg Chhatishgarh Prahlad
More informationSchool Nursing and Health. Standard Precautions. (aka Universal Precautions)
School Nursing and Health Standard Precautions (aka Universal Precautions) August 2016 1 Standard Precautions Occupational Safety and Health Administration Federal Law 29 CFR bloodborne Pathogens 1910.1030(g)(2)(i)
More informationBackground. that NAT screening could significantly reduce the rate of undetected HCV for all donor risk strata.
American Journal of Transplantation 2011; 11: 1201 1208 Wiley Periodicals Inc. C 2011 The Authors Journal compilation C 2011 The American Society of Transplantation and the American Society of Transplant
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091606 Age 24 Years Gender Male 30/8/2017 92800AM 30/8/2017 94631AM 31/8/2017 90306AM Ref By Final HEATITIS A & B VIRUS EVALUATION HEATITIS A ANTIBODY (ANTI HAV),
More informationHIV Testing. ECHO Hep C. Judith Feinberg, MD June 22, 2017
HIV Testing ECHO Hep C Judith Feinberg, MD June 22, 2017 Overview A few basics HIV epidemiology in the US HIV testing Time course of HIV-1 infection symptoms HIV proviral DNA symptoms window period HIV
More informationChanging eligibility criteria for MSM: The Canadian Perspective
Changing eligibility criteria for MSM: The Canadian Perspective Mindy Goldman MD Canadian Blood Services ASFA & WAA Joint Meeting, San Francisco April 4, 2014 Outline - Historical background - International
More informationProposed 1 st IS for Hepatitis E Virus RNA WHO/BS/
www.pei.de Proposed 1 st IS for Hepatitis E Virus RNA WHO/BS/09.2126 S. Baylis, Division of Virology, Paul-Ehrlich-Institut, Langen, Germany SoGAT XXII 14 th -15 th April 2011, Rome, Italy Presented at:
More informationTransfusion transmitted infections in National Haemovigilance Systems: the Greek experience
Transfusion transmitted infections in National Haemovigilance Systems: the Greek experience Global blood product safety 10 April 2019, Rome, Italy Constantina Politis National Coordinating Haemovigilance
More informationMSM DONOR POLICY: STUDIES FROM THE USA AND OTHER COUNTRIES. Brian Custer IPFA PEI Workshop Rome 22 May 2014
MSM DONOR POLICY: STUDIES FROM THE USA AND OTHER COUNTRIES Brian Custer IPFA PEI Workshop Rome 22 May 2014 Financial Disclosure Nothing to disclose International Context for Blood Donation by MSM Country
More informationGovernment of Canada Federal AIDS Initiative Milestones
HIV in Canada: Trends and Issues for Advancing Prevention, Care, Treatment and Support Through Knowledge Exchange Michael R Smith, Senior Policy Advisor, Programs and Coordination Division, Centre for
More informationHepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University
Hepatitis B ECHO November 29, 2017 Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University Disclosures Advisory board Gilead Comments The speaker Joseph
More informationIQPP Qualified Donor Standard
IQPP Qualified Donor Standard Background The is part of a series of standards that comprise the Plasma Protein Therapeutics Association (PPTA) IQPP Standards Program. PPTA's Voluntary Standards Program
More informationEDMA HIV-AIDS TEAM Fact Sheet November 2007
EDMA HIV-AIDS TEAM Fact Sheet November 2007 1. HIV Facts AIDS epidemic update UNAIDS Epidemic Update, November 2007 (1) 760,000 people to be living with HIV in Western and Central Europe in 2007. 31,000
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091608 Age 26 Years Gender Female 30/8/2017 92900AM 30/8/2017 94717AM 31/8/2017 90216AM Ref By Final HEATITIS ACUTE VIRUS CONFIRMATION HEATITIS A ANTIBODY (ANTI HAV),
More informationNAT Screening of Blood Donations in NBC, TRCS
IPFA/PEI, Italy NAT Screening of Blood Donations in NBC, TRCS 2000-2001 Clinical evaluation using COBAS AmpliiScreen HIV & HCV assays, (MP24) window period rate - 1 : 108,768 for HIV-1 and HCV 2002 Routine
More informationDISCOVERY OF FALSE HIV ELITE CONTROLLERS AMONG SOUTH AFRICAN BLOOD DONORS
DISCOVERY OF FALSE HIV ELITE CONTROLLERS AMONG SOUTH AFRICAN BLOOD DONORS SANBTC Sun City, South Africa 28 th 31 st August 2017 Marion Vermeulen, Karin van den Berg, Genevieve Jacobs, Brian Custer, Ronel
More informationIn the United States and in Canada, as in most other
BLOOD DONORS AND BLOOD COLLECTION The risks and benefits of accepting men who have had sex with men as blood donors M. Germain, R.S. Remis, and G. Delage BACKGROUND: It has been suggested that men who
More informationResearch Article Decision on conducting HCV Immunoblot and HCV Viral Load Tests Dependent upon the Result of the Screening Tests
IBIMA Publishing Journal of Virology & Microbiology http://www.ibimapublishing.com/journals/jvm/jvm.html Vol. 2013 (2013), Article ID 332501, 7 pages DOI: 10.5171/2013.332501 Research Article Decision
More informationHEV Assay Development Update
HEV Assay Development Update Jeffrey M. Linnen, Ph.D. Senior Director, Research & Development Hologic Gen-Probe, San Diego, California USA IPFA/PEI 20th International Workshop on Surveillance and Screening
More informationELPA S VISION OF SCREENING
ELPA S VISION OF SCREENING By Nadine Piorkowsky President of the European Liver Patients Association, Budapest, 18-19 March 2010 ELPA s network The Patient s View a viral time bomb: Up to 9 out of 10 chronic
More informationTGA regulation of local manufacturers of plasma derivatives CSL Behring Australia s overview
IPFA Workshop Session 7: REGULATORY CONSIDERATIONS TGA regulation of local manufacturers of plasma derivatives CSL Behring Australia s overview Mary Lavithis, CSL Behring Australia Presented at: IPFA Asia
More informationAPPROACH TO RISK MANAGEMENT IN MEDICAL PRACTICE: STANDPOINT OF THE BLOOD TRASFUSION*
11 APPROACH TO RISK MANAGEMENT IN MEDICAL PRACTICE: STANDPOINT OF THE BLOOD TRASFUSION* Hisami IKEDA** Asian Med. J. 44(1): 11 21, 2000 Abstract: In the field of blood transfusion, risk management is defined
More informationVersion for the Silent Procedure 29 April Agenda item January Hepatitis
Version for the Silent Procedure 29 April 2014 134th session EB134.R18 Agenda item 10.5 25 January 2014 Hepatitis The Executive Board, Having considered the report on hepatitis, 1 RECOMMENDS to the Sixty-seventh
More informationRole and missions of a National Reference center for blood borne agents: the French example
Role and missions of a National Reference center for blood borne agents: the French example Virginie Sauvage, PhD Département des Agents Transmissibles par le Sang, Centre National de Référence pour les
More informationHEPATITIS SCREENING IN THE LITHUANIAN BLOOD ESTABLISHMENTS. Joana Bikulčienė Director of National blood center
HEPATITIS SCREENING IN THE LITHUANIAN BLOOD ESTABLISHMENTS Joana Bikulčienė Director of National blood center j.bikulciene@kraujodonoryste.lt Organizational structure of Lithuanian blood service 1 specialized
More informationStudy of ChLIA and ELISA for TTI Markers in Blood Donors
Study of ChLIA and ELISA for TTI Markers in Blood Donors Presenting Author - Miss Kiran Kachhadiya (Co-authors: Dr. Vachhani N., Mrs. Bhatt J, Dr. Jani F., Dr. Nandani S.) Life Blood Centre (Formerly known
More informationHot Topics in Tissue Safety
Hot Topics in Tissue Safety 37 th Annual AATB Meeting National Harbor, Maryland 03 October 2013 Scott A. Brubaker, CTBS Chief Policy Officer PHS Guideline for Reducing Human Immunodeficiency Virus, Hepatitis
More informationTrends in molecular diagnostics
Trends in molecular diagnostics Detection of target genes of interest Quantification Infectious diseases HIV Hepatitis C & B TB / MAC Cytomegalovirus Herpes simplex Varicella zoster CT/GC HPV Profiling
More informationHepa%%s E Virus Is it a Concern?
IPFA/PEI 17 th Workshop on Surveillance and Screening of Blood Borne Pathogens 26-27 May 2010, The Regent Esplanade Zagreb Hotel, Zagreb, Croa%a Hepa%%s E Virus Is it a Concern? Keiji Matsubayashi Hokkaido
More informationGuide to the preparation, use and quality assurance of blood components
Contents Foreword...3 Members of the European Committee (Partial Agreement) on Blood Transfusion... 8 Members of the GTS working group... 22 Members of the TS066 working group... 30 Recommendation No.
More informationHIV-RNA reference panels
The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents Overview HIV-RNA panels for sensitivity analysis...
More informationIn October 2005, the South African National Blood
DONOR INFECTIOUS DISEASE TESTING Hepatitis B virus transmission by blood transfusion during 4 years of individual-donation nucleic acid testing in South Africa: estimated and observed window period risk_3355
More informationMoon Jung Kim 1, Quehn Park 2, Hyuk Ki Min 3 and Hyun Ok Kim 1*
Kim et al. BMC Infectious Diseases 2012, 12:160 RESEARCH ARTICLE Open Access Residual risk of transfusion-transmitted infection with human immunodeficiency virus, hepatitis C virus, and hepatitis B virus
More informationRecent advances in development and application of assays/algotithms for detection of recent HIV infections and estimation of incidence
Recent advances in development and application of assays/algotithms for detection of recent HIV infections and estimation of incidence Michael Busch, MD, PhD Blood Systems Research Institute University
More informationPlasma for fractionation: South African Plasma Requirements
Plasma for fractionation: South African Plasma Requirements Dr Jeh-han Omarjee Head: Microbiological Sciences NBI is a "not for profit" company committed to providing safe, cost effective, quality medicinal
More informationZIKA VIRUS AND SAFETY OF THE BLOOD SUPPLY. Michael P Busch, MD, PhD Blood Systems Research Institute University of California, San Francisco
ZIKA VIRUS AND SAFETY OF THE BLOOD SUPPLY Michael P Busch, MD, PhD Blood Systems Research Institute University of California, San Francisco ZIKV Risks of major TTVs linked to interventions, and accelerating
More informationTransfusion-transmitted HIV from seroconverted blood donors has not been identified in England since the introduction of HIV NAT screening
Transfusion-transmitted HIV from seroconverted blood donors has not been identified in England since the introduction of HIV NAT screening Bhavita Vishram Timeline of introduction of microbiological tests
More informationHEPATITIS C VIRUS: SCREENING, DIAGNOSIS, AND INTERPRETATION OF LABORATORY ASSAYS
IJCRR Section: Healthcare Sci. Journal Impact Factor 4.016 Research Article HEPATITIS C VIRUS: SCREENING, DIAGNOSIS, AND INTERPRETATION OF LABORATORY ASSAYS Amit H. Agravat 1, Mital J. Gamit 2, Gauravi
More informationHepatitis C Cure The Invisible Epidemic
Hepatitis C Cure The Invisible Epidemic Iris House 8 Th Annual Face of AIDS Summit Hadiyah Charles Hepatitis Advocacy Manager Harm Reduction Coalition Hepatitis C Basics A virus that can cause chronic
More informationWNV surveillance and prevention of transfusion transmission in Italy
Ministero del Lavoro, della Salute e delle Politiche Sociali Istituto Superiore di Sanità Centro Nazionale Sangue Via Giano della Bella, 27 00162 Roma Tel: 06 4990 4953 / 4954 Fax: 06 4990 4975 E-mail:
More informationJuly 14, Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852
July 14, 2015 Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Submitted via http://www.regulations.gov Re: Docket No. FDA-2015-D-1211
More informationHIV Basics: Clinical Tests and Guidelines
HIV Basics: Clinical Tests and Guidelines ACTHIV 2010 Zelalem Temesgen MD Mayo Clinic Topics Baseline laboratory evaluation Laboratory monitoring through the continuum of care Patients not on antiretroviral
More information